Research programme: anticancer therapeutics - CBT Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - CBT Pharmaceuticals

Alternative Names: CBT-102; CBT-502

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator CBT Pharmaceuticals
  • Developer CBT Pharmaceuticals; Chia Tai Tianqing Pharmaceutical Group
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Mitogen-activated protein kinase inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Sep 2016 CBT 502 licensed to Chia Tai TianQing in China (CBT Pharmaceuticals pipeline, September 2016)
  • 01 Sep 2016 Early research in Cancer in USA (PO) before September 2016 (CBT Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top